Antineoplastic Combined Chemotherapy Protocols/therapeutic use Bayes Theorem Carcinoma Transitional Cell/*drug therapy/pathology/surgery Cisplatin/therapeutic use Cystectomy Deoxycytidine/analogs & derivatives/therapeutic use Doxorubicin/therapeutic use Humans Methotrexate/therapeutic use *Neoadjuvant Therapy Neoplasm Invasiveness/pathology Urinary Bladder Neoplasms/*drug therapy/pathology/surgery Vinblastine/therapeutic use Gemcitabine

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage *Cystectomy/methods Evidence-Based Medicine Humans *Lymph Node Excision Neoadjuvant Therapy/*methods Neoplasm Invasiveness Organ Sparing Treatments/methods Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/*pathology/*therapy adjuvant chemotherapy bladder cancer bladder-sparing therapy lymph node dissection neoadjuvant chemotherapy radical cystectomy

Biomarkers Tumor/genetics DNA Methylation Epigenesis Genetic *Gene Expression Regulation Neoplastic Humans Prognosis Retrospective Studies Urinary Bladder Neoplasms/*genetics Chromatin remodeling Methylation Non-coding RNA Progression Recurrence Urothelial carcinoma

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review

Administration Intravesical Antineoplastic Agents/administration & dosage/*therapeutic use BCG Vaccine/administration & dosage/*therapeutic use Humans Treatment Outcome Urinary Bladder Neoplasms/*drug therapy

Administration Intravesical Antineoplastic Agents/*administration & dosage Antineoplastic Combined Chemotherapy Protocols/administration & dosage Carcinoma Transitional Cell/*drug therapy/mortality Cyclophosphamide/administration & dosage Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Melphalan/administration & dosage Network Meta-Analysis Semustine/administration & dosage Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality chemotherapy drug therapy single instillation systematic review urinary bladder neoplasm

Adult Aged Aged 80 and over Biomarkers Tumor/*metabolism Cyclin-Dependent Kinase Inhibitor p16/*metabolism *Down-Regulation Female Gene Expression Regulation Neoplastic Humans Lymphatic Metastasis Male Middle Aged Prognosis Survival Analysis Urinary Bladder Neoplasms/metabolism/mortality/*pathology